Example: Heart Attack

Search clinical trials for: Imatinib

Total 425 results

NCT04126681

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Conditions: Chronic Myeloid Leukemia, Chronic Phase
NCT00171158

Completed

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Conditions: Philadelphia Chromosome Positive CML
NCT01275222

Completed

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Conditions: Gastrointestinal Stromal Tumors
NCT03609424

Recruiting

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

Conditions: Gastrointestinal Stromal Tumors
NCT03589326

Recruiting

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
NCT01541709

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Conditions: Gastrointestinal Stromal Tumors
NCT03007147

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
NCT00070499

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
NCT04933669

Not yet recruiting

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

Conditions: Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant
NCT01392469

Completed

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

Conditions: Pulmonary Arterial Hypertension
NCT03891901

Recruiting

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

Conditions: Tuberculosis
NCT01738139

Recruiting

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Conditions: Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Unresectable Solid Neoplasm
NCT00044304

Recruiting

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Conditions: Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome
NCT02644525

Completed

Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa

Conditions: Loaisis
NCT03023046

Active, not recruiting

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
NCT04416750

Recruiting

Positioning Imatinib for Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT01991379

Recruiting

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Conditions: Gastrointestinal Stromal Tumor (GIST)
NCT01085617

Recruiting

Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Conditions: Leukemia, Mucositis, Oral Complications
NCT03578367

Active, not recruiting

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Conditions: CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
NCT02130557

Completed

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Conditions: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
NCT02081378

Recruiting

A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

Conditions: Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
NCT04877522

Not yet recruiting

Asciminib Roll-over Study

Conditions: Chronic Myelogenous Leukemia
NCT03112603

Active, not recruiting

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Conditions: Graft-versus-host Disease (GVHD)
NCT01742299

Active, not recruiting

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Conditions: GIST and CML
NCT00476190

Active, not recruiting

ALL Adult Consortium Trial: Adult ALL Trial

Conditions: Acute Lymphoblastic Leukemia